Considering the increasing importance of the role of matrisomes in tumors and their immune microenvironment, we constructed a risk signature using eight immune‐related matrisomes, namely, LIF, LOX, MMP9, S100A4, SRPX2, SLIT1, SMOC1, and TIMP1, to predict the survival and prognosis of glioma patients. The gene discussed is SRPX2; the disease is glioma.